Recently, Professor Zhang Shuyang, President of PUMCH, and Professor Tian Zhuang administered YOLT-201, China’s first domestically developed gene editing drug, to the first subject in the national multi-center clinical trial at the Clinical Pharmacology Center...

On July 21, 2024, PUMCH President Zhang Shuyang and Nancy Ip, President of Hong Kong University of Science and Technology (HKUST), signed a strategic cooperation agreement as representatives. The signing was witnessed by Wu Peixin and Han Ding, Vice Presidents...

From June 12 to 15, 2024, the European Alliance of Associations for Rheumatology (EULAR) 2024 Congress was held in Vienna, Austria. The rheumatology team of PUMCH delivered 5 oral presentations and 2 poster tours, making the voice of Chinese scholars heard on ...

Recently, the liver surgery team at PUMCH, in collaboration with several research institutes, made two major breakthroughs on artificial livers. The teams used embedded bioprinting to construct artificial liver with hepatic vein structures, and acoustical holo...